Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review

BACKGROUND: Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established. CASE PRESENTATION: We describe the case of a 47-year-old man with end-stage renal disease who rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Brizzi, M. P., La Salvia, A., Tampellini, M., Sonetto, C., Volante, M., Scagliotti, G. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861646/
https://www.ncbi.nlm.nih.gov/pubmed/29558899
http://dx.doi.org/10.1186/s12885-018-4205-0
_version_ 1783308129040072704
author Brizzi, M. P.
La Salvia, A.
Tampellini, M.
Sonetto, C.
Volante, M.
Scagliotti, G. V.
author_facet Brizzi, M. P.
La Salvia, A.
Tampellini, M.
Sonetto, C.
Volante, M.
Scagliotti, G. V.
author_sort Brizzi, M. P.
collection PubMed
description BACKGROUND: Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established. CASE PRESENTATION: We describe the case of a 47-year-old man with end-stage renal disease who received everolimus plus Lanreotide for 9 months for the management of metastatic atypical bronchial carcinoid. CONCLUSIONS: Everolimus is a treatment option for hemodialysis patients with metastatic atypical bronchial carcinoid. Based on our case report and review of literature, Everolimus does not require any dose reductions and is overall well tolerated in hemodialysis patients.
format Online
Article
Text
id pubmed-5861646
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58616462018-03-26 Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review Brizzi, M. P. La Salvia, A. Tampellini, M. Sonetto, C. Volante, M. Scagliotti, G. V. BMC Cancer Case Report BACKGROUND: Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established. CASE PRESENTATION: We describe the case of a 47-year-old man with end-stage renal disease who received everolimus plus Lanreotide for 9 months for the management of metastatic atypical bronchial carcinoid. CONCLUSIONS: Everolimus is a treatment option for hemodialysis patients with metastatic atypical bronchial carcinoid. Based on our case report and review of literature, Everolimus does not require any dose reductions and is overall well tolerated in hemodialysis patients. BioMed Central 2018-03-20 /pmc/articles/PMC5861646/ /pubmed/29558899 http://dx.doi.org/10.1186/s12885-018-4205-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Brizzi, M. P.
La Salvia, A.
Tampellini, M.
Sonetto, C.
Volante, M.
Scagliotti, G. V.
Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
title Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
title_full Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
title_fullStr Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
title_full_unstemmed Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
title_short Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
title_sort efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861646/
https://www.ncbi.nlm.nih.gov/pubmed/29558899
http://dx.doi.org/10.1186/s12885-018-4205-0
work_keys_str_mv AT brizzimp efficacyandsafetyofeverolimustreatmentinahemodialysispatientwithmetastaticatypicalbronchialcarcinoidcasereportandliteraturereview
AT lasalviaa efficacyandsafetyofeverolimustreatmentinahemodialysispatientwithmetastaticatypicalbronchialcarcinoidcasereportandliteraturereview
AT tampellinim efficacyandsafetyofeverolimustreatmentinahemodialysispatientwithmetastaticatypicalbronchialcarcinoidcasereportandliteraturereview
AT sonettoc efficacyandsafetyofeverolimustreatmentinahemodialysispatientwithmetastaticatypicalbronchialcarcinoidcasereportandliteraturereview
AT volantem efficacyandsafetyofeverolimustreatmentinahemodialysispatientwithmetastaticatypicalbronchialcarcinoidcasereportandliteraturereview
AT scagliottigv efficacyandsafetyofeverolimustreatmentinahemodialysispatientwithmetastaticatypicalbronchialcarcinoidcasereportandliteraturereview

Ejemplares similares